Objective: Recurrent hepatitis C virus (HCV) infection contributes to unfavourable outcomes in HIV/HCV coinfected liver transplant recipients. Direct-acting antiviral (DAA) therapies for HCV offer an opportunity to improve patient and allograft survival in this patient population. We evaluated treatment outcomes with sofosbuvir (SOF)-based DAA therapy among HIV/HCV coinfected liver transplant recipients.
Introduction
Hepatitis C virus (HCV) infection is a leading cause of non-AIDS mortality in patients infected with HIV [1] . Liver transplantation is feasible for HIV/HCV coinfected patients with end stage liver disease, albeit with lower patient and graft survival rates as compared with HCV monoinfected recipients. These suboptimal outcomes are often attributed to rapidly progressive or severe recurrent HCV [2] [3] [4] [5] [6] . Interferon (IFN)-based regimens for postliver transplant treatment of HCV have low efficacy and high rates of treatment-limiting complexities, with particularly low rates of virologic cure observed in coinfected recipients [7, 8] . Emerging therapies with direct-acting antivirals (DAAs) offer promise of high rates of HCV cure, fewer side-effects and improved outcomes after liver transplant. However, no rigorous clinical trial data regarding DAAs for HCV treatment among coinfected liver transplant recipients is available. As such, we sought to evaluate 'real world' treatment outcomes with DAAs among HIV/HCV coinfected liver transplant recipients at our centre.
Methods

Study population
The Northwestern University Viral Hepatitis Registry (NU-VHR) is a prospective cohort of HIV-infected adults coinfected with hepatitis B and/or C virus recruited at Northwestern Memorial Hospital in Chicago, Illinois, USA, since January 2013. For this analysis, we included subjects with chronic HCV infection who underwent liver transplant between 2007 and 2014. The Institutional Review Board of Northwestern University approved this study.
Clinical and laboratory protocols
Per our standardized clinical protocol, HIV/HCV coinfected patients were listed for liver transplant if they met preidentified criteria that mirrored those established in clinical trials [6, 9] . A multidisciplinary team provided clinical care to all recipients. All patients received combination antiretroviral therapy (cART) for HIV infection at the time of liver transplant. Immunosuppression included methylprednisolone followed by a prednisone taper and tacrolimus with specific tacrolimus goal levels based on renal function and duration of time posttransplant; mycophenolate mofetil was added in recipients with kidney disease (posttransplant protocol available in supplementary material, http://links.lww. com/QAD/A778). Liver biopsies were performed to investigate serum liver chemistry abnormalities or at least once in the first year posttransplantation.
HCV treatment choice and duration was based on existing guidelines for HCV monoinfection [15] . HCV genotype GT1 and GT2 infections were treated with sofosbuvir (SOF) and simeprevir (SMV) or ribavirin (RBV), respectively. Due to potential complex drug interactions between cART, tacrolimus, and simeprevir, a 'two-step' process for implementation of DAA therapy was utilized. First cART and tacrolimus modifications were made if needed; after stabilization of tacrolimus levels, DAAs were initiated. Standard doses of SOF, SMV, and RBV were utilized. Tacrolimus levels, haemoglobin and serum creatinine were monitored during therapy and patients were contacted regularly to audit medication adherence and adverse events.
Plasma hepatitis C virus RNA was quantified at baseline, end of treatment (EOT), and 12 weeks after DAA completion. Additional labs obtained at baseline and throughout therapy included tacrolimus levels, quantitative HIV RNA, CD4 þ T-cell counts, liver chemistries, haemoglobin, platelet counts, creatinine and INR. APRI (aspartate transaminase-to-platelet ratio index) and FIB-4 (Fibrosis-4) scores were calculated using standard methodologies [10] [11] [12] [13] .
Data collection
Clinical data abstracted from medical records included laboratory data as above and patient demographics, underlying liver disease, biopsy results, prior HCV treatment, comorbid conditions, antiretroviral and immunosuppressive therapies, transplant complications and rejection episodes.
Outcomes and statistical analysis
The primary study outcomes were sustained HCV viral response (HCV RNA 15 IU/ml) 12 weeks after DAA completion (SVR12) and treatment-related adverse events. Secondary outcomes were abnormalities in serum transaminase and bilirubin levels, sustained HIV viral nonsuppression (HIV RNA 20 copies/ml present on two or more consecutive samples), supra or subtherapeutic tacrolimus levels, and allograft rejection. Continuous variables were compared using Wilcoxon signedrank testing and Friedman's ANOVA (SPSS version 22.0; Armonk, New York; IBM Corp.).
Results
Clinical and transplant characteristics of HIV/HCV coinfected recipients
Of 164 liver transplants performed at our institution for HCV over the study period, nine coinfected liver transplant recipients were evaluated for DAA therapy; one was ineligible due to renal failure. Characteristics of the eight who received DAA therapies are described in Table 1 . All were male and predominantly whites (57%) with median age 51 years [interquartile range (IQR) 40.3-59 years]. Three failed IFN-based HCV therapy; (Table 1) .
Direct-acting antiviral treatment response
Seven recipients completed DAA therapy and achieved SVR12; the eighth expired during therapy (see below). Decreases in transaminases, total bilirubin, APRI score and FIB-4 score occurred in six of seven patients over the course of therapy; median changes are shown in Fig. 1 .
Drug modifications and drug-drug interactions
Patients on cART containing either efavirenz (EFZ; n ¼ 3) or atazanavir/ritonavir (ATZ/r; n ¼ 1) were changed to integrase inhibitor-based regimens prior to DAA initiation to avoid drug interactions. Tacrolimus doses were decreased in two patients after discontinuing EFZ and increased in the patient who discontinued ATZ/ r. The patient receiving SOF/RBV underwent no cART adjustments but required first an increased then a reduced tacrolimus dose throughout DAA therapy. Additionally two patients with fluctuating kidney function during DAA therapy required tenofovir dosing adjustments. There were no significant differences in median tacrolimus levels obtained at baseline, after 4 weeks of therapy, and after completion of therapy (Table 1) however four patients experienced subtherapeutic tacrolimus levels during or shortly after DAA therapy. There were no toxic levels of tacrolimus and no sustained episodes of HIV virologic nonsuppression during DAA therapy.
Adverse effects of anti-HCV therapy
Adverse effects were assessed by regular phone contact with the pharmacist and by physicians at clinical visits during DAA therapy. The frequency and severity of ontreatment adverse effects were minimal and are summarized in Table 1 . There were no adverse effect-related HCV DAA discontinuations. RNA after 1 week of treatment, progressive MSOF prompted the decision to withdraw care.
Discussion
We herein report excellent treatment outcomes and tolerability in the largest number to date of HIV/HCV coinfected liver transplant recipients treated with HCV DAAs, specifically SOF with SMV or RBV. Our results are comparable to, if not better than, those observed in studies of HCV monoinfected, nontransplant patients. Although no clinical trial has assessed SOF/SMV in HIV/ HCV coinfected patients or liver transplant recipients, 'real world' data in HIV/HCV nontransplant patients shows this regimen to be highly effective [14, 15] . Clinical trials of other DAA combinations in monoinfected liver transplant recipients also demonstrate high SVR12 rates; 96-98% of noncirrhotic recipients achieved SVR12 using SOF/ledipasvir or ombitasvir/paritaprevir/r with dasabuvir and ribavirin (3D þ RBV) [16, 17] . Lower rates of virologic response were noted within nonclinical trialbased observational cohorts and among patients with advanced fibrosis or cirrhosis [18, 19] .
Published studies of DAA treatment in HIV/HCV coinfected liver transplant recipients are limited. Campos-Varela et al. described two HIV-infected liver transplant recipients with HCV GT1a, one with decompensated cirrhosis and the other with severe cholestatic recurrent HCV and cirrhosis, who were treated with 24 weeks of SOF/RBV followed by 12 weeks of SOF/SMV/RBV to achieve SVR12 [20] . Our recipients, though with less advanced liver disease, were successfully treated with significantly shorter durations of HCV DAA therapy and without the addition of ribavirin for GT1-infected persons, reducing financial costs and potential adverse effects.
Though we observed minimal HCV DAA-related adverse effects and no treatment-related DAA discontinuations, frequent medication adjustments were required, emphasizing the need for intensive clinical monitoring. One patient developed acute cellular rejection after completing HCV therapy in the setting of an undetectable tacrolimus level. Simeprevir may reduce tacrolimus levels; however, given the time course of this episode and documented therapeutic tacrolimus levels during and immediately after DAA therapy, it is not likely that DAAs contributed substantively to this episode. One patient died during SOF/SMV therapy; he was critically ill at treatment initiation and supportive care was withdrawn when he failed to clinically improve. Although SMV has been associated with hepatic decompensation in patients with advanced liver disease, it was not considered a factor in this patient's clinical course [21] .
This study was conducted at a single centre among a small cohort, potentially limiting the generalizability of the findings. Most patients had minimal post-liver transplant liver disease, which is not representative of HIV/HCV coinfected liver transplant recipients with more aggressive post-liver transplant HCV infection recurrence or advanced fibrosis. Additionally our cohort demonstrated generally excellent medication adherence and follow-up. These factors combined with intensive multidisciplinary patient care likely contributed to our observed DAA treatment success.
In summary, our results indicate that combinations of SOF/SMV for GT1 and SOF/RBV for GT2 patients are feasible therapeutic regimens for patients with post-liver transplant recurrent HCV and mild to moderate liver fibrosis. Longer durations or more complex regimens are not necessary solely for the reason of liver transplant. Although DAAs with fewer drug interactions than SMV are now available, this agent is well tolerated and efficacious in noncirrhotic patients with HCV GT1 and thus remains a treatment option for select patients [22] . In the context of limited and less than ideal liver transplant outcomes among HIV/HCV coinfected persons, it seems prudent to target this high-risk population for prompt receipt of DAA therapy. As HCV treatment prior to liver transplant may be difficult or less efficacious for patients with renal failure or decompensated cirrhosis, treating such patients early after transplant is emerging as an important strategy that may significantly improve patient and graft survival.
Summary
HIV/HCV coinfected patients experience lower graft survival and higher mortality after liver transplantation than HCV monoinfected patients. DAA treatment may improve outcomes though data are limited in coinfected patients. High rates of sustained viral response at week 12 posttherapy were achieved in this single-centre study.
